Core Insights - Soleno Therapeutics has recently received FDA approval for its first drug, VYKAT, targeting Prader-Willi Syndrome, and has successfully launched the product [4]. Company Overview - Soleno Therapeutics operates in the rare disease sector, focusing on Prader-Willi Syndrome with a single approved asset [4]. - The company reported a strong launch performance, achieving 646 start forms and engaging 295 prescribers within three months post-launch, exceeding initial expectations [4].